TABLE 1.
Clinical characteristics of the study groups of patients
| Anthropometric variables | LC control | LC-COPD |
| Subjects n | 20 | 30 |
| Age years | 65±7 | 69±8 |
| Male/female n | 13/7 | 26/4 |
| BMI kg·m−2 | 25.6±4 | 27.9±4* |
| Smoking history n (%) | ||
| Current | 6 (30) | 6 (20) |
| Ex-smoker | 6 (30) | 24 (80)* |
| Never-smoker | 8 (40) | 0 (0)* |
| Smoking pack-years | 37±37 | 61±18* |
| Lung function parameters | ||
| FEV1 | 83±17 | 68±14*** |
| FEV1/FVC % | 75±6 | 59±9*** |
| DLCO % | 82±16 | 60±12*** |
| KCO % | 83±14 | 63±15*** |
| GOLD stage n (%) | ||
| GOLD stage I | NA | 4 (13) |
| GOLD stage II | NA | 25 (83) |
| GOLD stage III | NA | 1 (3) |
| GOLD stage IV | NA | 0 (0) |
| TNM staging n (%) | ||
| Stage I | 8 (40) | 10 (33) |
| Stage II | 5 (25) | 14 (47) |
| Stage III | 7 (35) | 5 (17) |
| Stage IV | 0 (0) | 1 (3) |
| Histological diagnosis n (%) | ||
| Squamous cell carcinoma | 4 (20) | 8 (27) |
| Adenocarcinoma | 11 (55) | 21 (70) |
| Others | 5 (25) | 1 (3) |
| Blood parameters | ||
| Total leukocytes per μL | 8.53±2.8×103 | 8.85±2.4×103 |
| Total neutrophils per μL | 5.48±2.6×103 | 5.51±2×103 |
| Total lymphocytes per μL | 2.24±0.6×103 | 2.15±0.8×103 |
| Albumin g·dL−1 | 4.39±0.4 | 4.28±0.4 |
| Total proteins g·dL−1 | 7.22±0.5 | 7.05±0.4 |
| Body weight loss kg, n (%) | ||
| 0 | 18 (90) | 29 (97) |
| 1–5 | 1 (5) | 0 (0) |
| 6–10 | 1 (5) | 1 (3) |
Continuous variables are reported as mean±sd, categorical variables are expressed as the number of patients per group and the respective percentage in each group with respect to the total population. LC: lung cancer; BMI: body mass index; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; DLCO: diffusing capacity of the lung for carbon monoxide; KCO: Krogh transfer factor; GOLD: Global Initiative for Chronic Obstructive Lung Disease; NA: not applicable; TNM: tumour, nodes, metastasis. Statistical significance: *: p<0.05; ***: p<0.001 between LC-COPD and LC patients.